Purpose

The purpose of this study was to compare the neovascularization inhibiting the effect of topical bevacizumab and sorafenib and to determine the effective dose of sorafenib.

Material and Methods

Forty-two healthy Wistar albino rats were randomly divided into six groups. The right corneas of all rats except group 1 were cauterised with silver nitrate. Group 2 received DMSO, group 3 received topical bevacizumab (5 mg/dL, 3 times a day) and group 4, 5 and 6 received topical sorafenib (2.5 mg/dl, 5 mg/dL, 7.5 mg/dL, 2 times a day respectively), between days 1 and 7. Corneal photographs were taken on day 8 and the corneal neovascular area percentage was calculated. Following decapitation, the corneas were removed to determine the levels of VEGF ELİSA and corneal immune staining. The Mann–Whitney U-test was used for statistical analysis

Results

The neovascular corneal area percentage was statistically significantly lower in the treatment groups than group 2 (p < 0.05). The intensity of VEGF immune staining was also lower in groups 3, 5 and 6 from the group 2. Group 3, 5 and 6 were no significant differences compared to group 1. The VEGF ELİSA levels were statistically significantly lower in group 3, 5 and 6 compared to group 2 (p < 0.05). There was no statistically difference between VEGF ELİSA levels of group 2 and 4 (p > 0.05)

Conclusions

Sorafenib was as effective as bevacizumab in the regression of corneal neovascularization. The effect of sorafenib seems to be dose-dependent. The low doses and twice a day administration are important advantages of sorafenib.

中文翻译：

---

局部贝伐单抗和索拉非尼在实验性角膜新生血管中的作用比较。

目的

这项研究的目的是比较新血管形成对局部贝伐单抗和索拉非尼的抑制作用，并确定索拉非尼的有效剂量。

材料与方法

42只健康的Wistar白化病大鼠随机分为六组。除第1组外，所有大鼠的右角膜均用硝酸银烧灼。第2组接受DMSO，第3组接受局部贝伐单抗（5 mg / dL，每天3次），第4、5和6组接受局部索拉非尼（2.5 mg / dl，5 mg / dL，7.5 mg / dL，一次2次）分别在第1天和第7天之间。在第8天拍摄了角膜照片，并计算了角膜新生血管面积百分比。断头后，去除角膜以确定VEGFELİSA的水平和角膜免疫染色。使用Mann–Whitney U检验进行统计分析

结果

治疗组的新生血管角膜面积百分比在统计学上显着低于第2组（p  <0.05）。与第1组相比，第3、5和6组的VEGF免疫染色强度也较低。与第1组相比，第3、5和6组没有显着差异。在第3、5和6组中，VEGFELİSA水平明显降低。与第2组相比，差异为6（p  <0.05）。第2组和第4组的VEGFELİSA水平之间无统计学差异（p  > 0.05）

结论

在角膜新生血管消退中，索拉非尼与贝伐单抗一样有效。索拉非尼的作用似乎是剂量依赖性的。低剂量和每天两次给药是索拉非尼的重要优势。